July 05, 2022
2 min read
The authors report no relevant financial disclosures.
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
ADDED TO EMAIL ALERTS
We were unable to process your request. Please try again later. If you continue to have this issue please contact email@example.com. Back to Healio
Most patients with immune-mediated inflammatory diseases who had weakened responses to a standard vaccine series for COVID-19 mounted a serological response to a third dose, according to data published in Arthritis and Rheumatology. “The utility of a third vaccine dose in immunocompromised patients, as well as in the general population, is an urgent question in the global medical community and for policy makers,” Silje W. Syversen, MD, PhD, of Diakonhjemmet Hospital, in Oslo, Norway, and co-authors wrote.
Most patients with immune-mediated inflammatory diseases who had weakened responses to a standard vaccine series for COVID-19 mounted a serological response to a third dose, according to data. Source: Adobe Stock
“Findings of a recent study suggested that immunocompromised recipients of a solid organ transplant benefited from a third vaccine dose,” they added. “Apart from a study of a third dose of vaccine in rituximab-treated RA patients, only a case report and small studies (involving 33 or 17 participants) have been published regarding the immunogenicity and safety of a third dose in IMID patients who were receiving other therapies and had no response to the 2-dose vaccination regimen.” To analyze vaccine response following the standard two-dose regimen and a third dose in patients with immune-mediated inflammatory diseases (IMIDs) using immunosuppressive therapies, Syversen and colleagues conducted Nor-vaC, an ongoing observational study. Adults with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis or Crohn’s disease were recruited upon receipt of a COVID-19 vaccine, with those deemed eligible invited to participate before the roll out of Norway’s national vaccination program in February 2021. Volunteer health care workers made up the control group. Patients who mounted weak responses to the standard two-dose course after 4 weeks of follow-up were recruited into a separate intervention study and received a third dose between July 2021 and August 2021. The main endpoints of the investigation were the proportion of patients who mounted an appropriate serological response, and the anti-RBD levels following a standard course as well as a third dose o …